相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies
Philippe Armand et al.
LEUKEMIA (2021)
Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
Tycel J. Phillips et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
Patrick J. Engelberts et al.
EBIOMEDICINE (2020)
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
V Moreno et al.
ANNALS OF ONCOLOGY (2020)
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
Andrew M. Evens et al.
CLINICAL CANCER RESEARCH (2020)
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
Kamira Maharaj et al.
BLOOD ADVANCES (2020)
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles et al.
LANCET ONCOLOGY (2020)
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Philippe Armand et al.
BLOOD (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
Targeting Casein Kinase 1 (CK1) in Hematological Cancers
Pavlina Janovska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Chaitra S. Ujjani et al.
BLOOD (2020)
Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial
Nathan H. Fowler et al.
BLOOD (2020)
A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Tae Min Kim et al.
BLOOD (2020)
Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
Sarit E. Assouline et al.
BLOOD (2020)
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
Martin Hutchings et al.
BLOOD (2020)
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
Antonio Cuneo et al.
HEMATOLOGICAL ONCOLOGY (2019)
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Emerging epigenetic-modulating therapies in lymphoma
David Sermer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma
Zhi-Zhang Yang et al.
CELL REPORTS (2019)
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Franck Morschhauser et al.
LANCET HAEMATOLOGY (2019)
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Emmanuel Bachy et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning et al.
BLOOD (2019)
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Franck Morschhauser et al.
LANCET HAEMATOLOGY (2019)
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia
Ian W. Flinn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)
Satoko Morishima et al.
BLOOD (2019)
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
Petra Hillmann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Rajat Bannerji et al.
BLOOD (2019)
Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
Loretta J. Nastoupil et al.
BLOOD (2019)
A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma
Nathan H. Fowler et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Follicular lymphoma: 2018 update on diagnosis and management
Arnold Freedman
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Tycel J. Phillips et al.
BLOOD (2018)
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2018)
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Ajay K. Gopal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano et al.
LANCET ONCOLOGY (2018)
Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.
Laurie Helen Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Acalabrutinib combined with PI3K delta inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.
Paul M. Barr et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
F. Morschhauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival
Xiaoqing Lu et al.
BLOOD (2018)
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Nancy L. Bartlett et al.
BLOOD (2018)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization
Eleni Vergadi et al.
JOURNAL OF IMMUNOLOGY (2017)
PI3Kγ Activates Integrin α4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression
Philippe Foubert et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
Sonali M. Smith et al.
LANCET HAEMATOLOGY (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
Connie L. Batlevi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Maria-Elisabeth Goebeler et al.
LEUKEMIA & LYMPHOMA (2016)
Epigenetic dysregulation in follicular lymphoma
Shamzah Araf et al.
EPIGENOMICS (2016)
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation
Lapo Alinari et al.
BLOOD (2015)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Elayne Chan-Penebre et al.
NATURE CHEMICAL BIOLOGY (2015)
The PI3K-PKB/Akt Pathway
Brian A. Hemmings et al.
Cold Spring Harbor Perspectives in Biology (2015)
DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID
Pilar M. Dominguez et al.
CELL REPORTS (2015)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Michinori Ogura et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma
Jacob P. Smeltzer et al.
CLINICAL CANCER RESEARCH (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma
Jessica Okosun et al.
NATURE GENETICS (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
PI3K signaling in B cell and T cell biology
Klaus Okkenhaug et al.
FRONTIERS IN IMMUNOLOGY (2014)
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
Josee Golay et al.
BLOOD (2013)
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
Ling-Hua Zhang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Beguelin et al.
CANCER CELL (2013)
Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
Yasuhiro Oki et al.
CLINICAL CANCER RESEARCH (2013)
Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide
Jake Y. Henry et al.
IMMUNOLOGY (2013)
Protein Arginine Methyltransferase 5 (PRMT5) Inhibition Induces Lymphoma Cell Death through Reactivation of the Retinoblastoma Tumor Suppressor Pathway and Polycomb Repressor Complex 2 (PRC2) Silencing
Jihyun Chung et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
The phosphoinositice 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation, and impact on cellular functions
Samantha D. Pauls et al.
FRONTIERS IN IMMUNOLOGY (2012)
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elias Campo et al.
BLOOD (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
A Phase I Study of the Combination of Azacitidine, Cyclophosphamide, Vincristine, and Rituximab in Relapsed and Refractory Lymphoma
Jessica J. Moss et al.
BLOOD (2011)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
Alan G. Ramsay et al.
BLOOD (2009)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
PD-1 expression is markedly upregulated on intratumoral CD4+ and CD8+ T cells in follicular lymphoma and is associated with T-Cell exhaustion
Durgha Nattamai et al.
BLOOD (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome
Abigail M. Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
Joaquim Carreras et al.
BLOOD (2006)
The bcl-2/IgH rearrangement in a population of 204 healthy individuals:: Occurrence, age and gender distribution, breakpoints, and detection method validity
C Schmitt et al.
LEUKEMIA RESEARCH (2006)
Analysis of multiple biomarkers, shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)
P Farinha et al.
BLOOD (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
SS Dave et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Essential, nonredundant role for the phosphoinositide 3-kinase p110δ in signaling by the B-cell receptor complex
ST Jou et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Frequency of the Bcl-2/IgH rearrangement in normal individuals:: Implications for the monitoring of disease in patients with follicular lymphoma
KE Summers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
